A group of companies calling itself the “CoVIg-19 Plasma Alliance”, led by Takeda Pharmaceutical Company Limited. and CSL Behring, is poised to start a randomized trial for hyperimmune globulin – a potentially more potent and convenient alternative to convalescent plasma therapy.
The move is significant as convalescent plasma has just been given an Emergency Use Authorization (EUA) by the US Food...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
